.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,613,950

« Back to Dashboard

Claims for Patent: 8,613,950

Title:Pharmaceutical forms with improved pharmacokinetic properties
Abstract: The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.
Inventor(s): Serno; Peter (Gladbach, DE), Heinig; Roland (Wuppertal, DE), Pauli; Kerstin (Dortmund, DE), Hayauchi; Yutaka (Leverkusen, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:11/885,019
Patent Claims: 1. A drug formulation of vardenafil which disintegrates rapidly in the mouth, comprising: an uncoated tablet which disintegrates rapidly in the mouth and which releases the vardenafil in the mouth without swallowing the tablet, said tablet comprising vardenafil hydrochloride trihydrate, and at least one sugar alcohol, and wherein at least 80% of the vardenafil hydrochloride trihydrate in the drug formulation dissolves at 25.degree. C. in 10 ml of physiological saline, and further wherein the rate of release of the vardenafil hydrochloride trihydrate from the drug formulation in 900 ml of physiological saline within the first 5 minutes in the USP pedal stirrer apparatus at 50 rotations per minute at 37.degree. C. is at least 70%.

2. The drug formulation according to claim 1, wherein the vardenafil hydrochloride trihydrate is in micronized form with a mean particle size of less than 20 .mu.m.

3. The drug formulation according to claim 1 or claim 2, wherein said sugar alcohol comprises from 40% to 99% of the total formulation.

4. The drug formulation according to claim 1 or 2, wherein said sugar alcohol is selected from the group consisting of sorbitol, mannitol and mixtures thereof.

5. The drug formulation according to claim 4, wherein said sugar alcohol is mannitol.

6. The drug formulation of claim 4, wherein said sugar alcohol is sorbitol.

7. The drug formulation according to claim 4, wherein said vardenafil hydrochloride trihydrate comprises from 0.8% to 25% of the formulation, calculated as vardenafil free base.

8. A drug formulation in the form of an uncoated tablet which disintegrates rapidly in the mouth and releases the drug in the mouth without swallowing the tablet comprising vardenafil hydrochloride trihydrate, and at least two sugar alcohols.

9. The drug formulation according to claim 8, wherein said sugar alcohols are a mixture of sorbitol and mannitol.

10. The drug formulation according to claim 8, wherein at least one sugar alcohol is mannitol.

11. The drug formulation of claim 8, wherein at least one sugar alcohol is sorbitol.

12. The drug formulation according to claim 8, wherein said vardenafil hydrochloride trihydrate comprises from 0.8% to 25% of the formulation, calculated as vardenafil free base.

13. The drug formulation according to claim 8, wherein at least 80% of the vardenafil hydrochloride trihydrate in the drug formulation dissolves at 25.degree. C. in 10 ml of physiological saline.

14. The drug formulation according to claim 8, wherein the rate of release of the vardenafil hydrochloride trihydrate from the drug formulation in 900 ml of physiological saline within the first 5 minutes in the USP pedal stirrer apparatus at 50 rotations per minute at 37.degree. C. is at least 70%.

15. The drug formulation according to claim 8, wherein at least 80% of the vardenafil hydrochloride trihydrate in the drug formulation dissolves at 25.degree. C. in 10 ml of physiological saline and the rate of release of the vardenafil from the drug formulation in 900 ml of physiological saline within the first 5 minutes in the USP pedal stirrer apparatus at 50 rotations per minute at 37.degree. C. is at least 70%.

16. The drug formulation according to claim 8 or 12, comprising from 40% to 99% sugar alcohol of the total formulation.

17. A drug formulation in the form of an uncoated tablet which disintegrates rapidly in the mouth and releases vardenafil hydrochloride trihydrate in the mouth without swallowing the tablet, said tablet comprising vardenafil hydrochloride trihydrate; sorbitol; and mannitol; and wherein: said vardenafil hydrochloride trihydrate is in micronized form with a mean particle size of less than 20 .mu.m; said vardenafil hydrochloride trihydrate comprises from 0.8% to 25% of the formulation, calculated as vardenafil free base; and said sorbitol and mannitol together comprises from 40% to 99% of the formulation.

18. The drug formulation of claim 4, wherein said sugar alcohol is a mixture of mannitol and sorbitol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc